bms-777607
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00605618)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Also potent inhibitor of MST1R, AXL and TYRO3.
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1- Mol. weight
- 512.9 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL460702 ↗
Also known as
- bms777607
- bms 777607
- bms 777607
- bms 777607
- bms-777607
- bms-777607
- bms-777607
- bms-777607
- bms-777607
- n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01721148 | Phase 1 | Oct 1, 2012 | Aslan Pharmaceuticals |
| NCT00605618 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2008 | Bristol-Myers Squibb |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aslan Pharmaceuticals | For profit | 1 | 1 | 1 | 2012 |
| Bristol-Myers Squibb | For profit | 1 | 1 | 1 | 2008 |
2 organizations
Page 1 / 1